They also demonstrated greater percentage of TIM-3 positivity on peripheral CD4+ and CD8+ T cells from glioma patient tissues (58% of which were glioblastoma) compared to peripheral CD4+ and CD8+ T cells from healthy controls [71]. This evidence concerns the gene CD8A and glioblastoma.